Dexpramipexole | (R)-Pramipexole;R-(+)-Pramipexole;KNS-760704 | (R)-普拉克索 | Dopamine Receptor

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	1周咨询	- +

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01711866	Advanced Idiopathic Parkinson'... 展开 >>s Disease 收起 <<	Phase 4	Completed	-	United States, Alabama ... 展开 >> 505 Anniston, Alabama, United States United States, Florida 506 Atlantis, Florida, United States 508 Miami Springs, Florida, United States United States, Georgia 502 Atlanta, Georgia, United States United States, Ohio 501 Dayton, Ohio, United States United States, Oklahoma 509 Oklahoma City, Oklahoma, United States Korea, Republic of 101 Busan, Korea, Republic of 102 Busan, Korea, Republic of 108 Daegu, Korea, Republic of 109 Daegu, Korea, Republic of 105 Gyeonggi-Do, Korea, Republic of 103 Seoul, Korea, Republic of 104 Seoul, Korea, Republic of 106 Seoul, Korea, Republic of 107 Seoul, Korea, Republic of Malaysia 202 Sarawak, Malaysia Singapore 401 Singapore, Singapore 403 Singapore, Singapore Taiwan 301 Linkou, Taiwan 304 Taichung, Taiwan 305 Taipei, Taiwan 收起 <<
NCT01711866	-		Completed	-	-
NCT00144209	Restless Legs Syndrome	Phase 3	Completed	-	Switzerland ... 展开 >> Boehringer Ingelheim Investigational Site Basel, Switzerland, 4025 Boehringer Ingelheim Investigational Site Basel, Switzerland, 4031 Boehringer Ingelheim Investigational Site Bern, Switzerland, 3000 Boehringer Ingelheim Investigational Site Lugano, Switzerland, CH-6900 Boehringer Ingelheim Investigational Site Zurich, Switzerland, 8091 Boehringer Ingelheim Investigational Site Zurzach, Switzerland, 5330 收起 <<
NCT00614575	-		Completed	-	-
NCT03642964	Major Depressive Disorder (MDD... 展开 >>) 收起 <<	Phase 2	Active, not recruiting	January 30, 2019	United States, California ... 展开 >> Collaborative Neuroscience Network Long Beach, California, United States, 90806 收起 <<
NCT03683225	Idiopathic Parkinson Disease	Phase 2	Not yet recruiting	March 1, 2020	-
NCT00615914	-		Completed	-	-
NCT00614575	-		Completed	-	-
NCT00615914	-		Completed	-	-
NCT00240409	Parkinson Disease	Phase 3	Completed	-	China ... 展开 >> First Hospital of Beijing University Beijing, China, 100034 Beijing Tian Tan Hospital Beijing, China, 100050 Beijing Hospital Beijing, China, 100730 Peking Union Medical College Hospital Beijing, China, 100730 General Hospital of PLA Beijing, China, 100853 Shanghai Rui Jin Hospital Shanghai, China, 200025 Hua Shan Hospital, Fu Dan University Shanghai, China, 200040 收起 <<
NCT00804479	-		Terminated(Funding for the CAL... 展开 >>M-PD Cohort Study was terminated by sponsor.) 收起 <<	-	United States, New York ... 展开 >> University of Rochester Rochester, New York, United States, 14620 收起 <<
NCT02233023	Parkinson Disease	Phase 4	Completed	-	-
NCT02025608	Restless Legs Syndrome	Phase 4	Completed	-	Switzerland ... 展开 >> Neurocenter of Southern Switzerland Lugano, Ticino, Switzerland, 6903 Department of Neurology, Inselspital Bern, Switzerland, 3010 收起 <<
NCT01097421	-		Completed	-	-
NCT02262546	Healthy	Phase 1	Completed	-	-
NCT00681863	Tourette Syndrome	Phase 3	Terminated(Terminated for slow... 展开 >> enrollment.) 收起 <<	-	United States, Florida ... 展开 >> 248.642.0026 Boehringer Ingelheim Investigational Site Bradenton, Florida, United States 248.642.0025 Boehringer Ingelheim Investigational Site Tampa, Florida, United States United States, Georgia 248.642.0006 Boehringer Ingelheim Investigational Site Columbus, Georgia, United States United States, Massachusetts 248.642.0005 Boehringer Ingelheim Investigational Site Cambridge, Massachusetts, United States United States, New York 248.642.0003 Boehringer Ingelheim Investigational Site Manhasset, New York, United States 248.642.0009 Boehringer Ingelheim Investigational Site New York, New York, United States 248.642.0018 Boehringer Ingelheim Investigational Site New York, New York, United States 248.642.0013 Boehringer Ingelheim Investigational Site Orangeburg, New York, United States United States, Oklahoma 248.642.0029 Boehringer Ingelheim Investigational Site Oklahoma City, Oklahoma, United States United States, Rhode Island 248.642.0010 Boehringer Ingelheim Investigational Site Providence, Rhode Island, United States United States, Tennessee 248.642.0030 Boehringer Ingelheim Investigational Site Memphis, Tennessee, United States United States, Texas 248.642.0008 Boehringer Ingelheim Investigational Site Houston, Texas, United States United States, Virginia 248.642.0023 Boehringer Ingelheim Investigational Site Norfolk, Virginia, United States Germany 248.642.49004 Boehringer Ingelheim Investigational Site Ulm, Germany 收起 <<
NCT00152958	Restless Legs Syndrome	Phase 3	Completed	-	Germany ... 展开 >> Clinpharm International GmbH & Co. KG Berlin (Hellersdorf), Germany Boehringer Ingelheim Investigational Site Berlin, Germany Charité Campus Virchow-Klinikum Berlin, Germany emovis GmbH Berlin, Germany Boehringer Ingelheim Investigational Site Chemnitz, Germany ClinPharm Internat. GmbH & Co. KG Görlitz, Germany Paracelsus-Elena-Klinik Kassel, Germany ClinPharm International GmbH & Co. KG Leipzig, Germany Neurologische Klinik der Otto-von-Guericke-Universität Magdeburg, Germany Universitätsklinikum Giessen und Marburg Marburg, Germany Boehringer Ingelheim Investigational Site München, Germany Boehringer Ingelheim Investigational Site Würzburg, Germany 收起 <<
NCT00596115	-		-	-	-
NCT00152997	Restless Legs Syndrome	Phase 2	Completed	-	Japan ... 展开 >> Boehringer Ingelheim Investigational Site Akita, Akita, Japan Boehringer Ingelheim Investigational Site Kochi, Kochi, Japan Boehringer Ingelheim Investigational Site Kurume, Fukuoka, Japan Boehringer Ingelheim Investigational Site Otaru,Hokkaido, Japan Boehringer Ingelheim Investigational Site Sakai, Osaka, Japan Boehringer Ingelheim Investigational Site Shibuya,Tokyo, Japan Boehringer Ingelheim Investigational Site Takatsuki, Osaka, Japan 收起 <<
NCT00681863	-		Terminated(Terminated for slow... 展开 >> enrollment.) 收起 <<	-	-
NCT00274131	Parkinson Disease	Phase 3	Completed	-	-
NCT00133198	Restless Legs Syndrome	Phase 3	Completed	-	-
NCT00349531	Restless Legs Syndrome	Phase 4	Completed	-	-
NCT00275457	Restless Legs Syndrome	Phase 3	Completed	-	Austria ... 展开 >> Univ.-Klinik für Neurologie Graz, Austria, 8036 Univ.-Klinik für Neurologie Innsbruck, Austria, 6020 AKH der Stadt Linz Linz, Austria, 4021 Confraternität Privatklinik Wien, Austria, 1080 AKH Universitätsklinik für Psychiatrie Wien, Austria, 1090 Sonderkrankenanstalt für neurologischen und Wien, Austria, 1130 Wilhelminenspital der Stadt Wien Wien, Austria, 1160 Germany Boehringer Ingelheim Investigational Site Bad Dürrheim-Sunthausen, Germany, 78073 Boehringer Ingelheim Investigational Site Bad Krozingen, Germany, 79189 Boehringer Ingelheim Investigational Site Berlin, Germany, 10625 emovis GmbH Berlin, Germany, 10629 Facharzt für Neurologie Emmendingen, Germany, 79312 Boehringer Ingelheim Investigational Site Kehl, Germany, 77694 ClinPharm International GmbH & Co. KG Leipzig, Germany, 04229 Universitätsklinikum Giessen und Marburg Marburg, Germany, 35039 Netherlands Boehringer Ingelheim Investigational Site Beek en Donk, Netherlands, 5741 AR Boehringer Ingelheim Investigational Site Den Haag, Netherlands, 2585 LJ Boehringer Ingelheim Investigational Site Deurne, Netherlands, 5751 XJ Boehringer Ingelheim Investigational Site Ewijk, Netherlands, 6644 CL Boehringer Ingelheim Investigational Site Lichtenvoorde, Netherlands, 7131 CM Boehringer Ingelheim Investigational Site Rijswijk, Netherlands, 2281 AK Boehringer Ingelheim Investigational Site Roelofarendsveen, Netherlands, 2371 RB Boehringer Ingelheim Investigational Site Rotterdam, Netherlands, 3082 DC Norway Boehringer Ingelheim Investigational Site Hamar, Norway, N-2317 Boehringer Ingelheim Investigational Site Oslo, Norway, N-0159 Boehringer Ingelheim Investigational Site Oslo, Norway, N-0303 Boehringer Ingelheim Investigational Site Tønsberg, Norway, N-3111 Sweden Boehringer Ingelheim Investigational Site Göteborg, Sweden, 413 45 Stockholms Neuro Center Stockholm, Sweden, 112 81 Neurologkliniken Stockholm, Sweden, 141 86 Boehringer Ingelheim Investigational Site Uppsala, Sweden, 751 85 Läkarhuset Vällingby Vällingby, Sweden, 162 68 Boehringer Ingelheim Investigational Site Västra Frölunda, Sweden, 421 30 Boehringer Ingelheim Investigational Site Örebro, Sweden, 701 85 收起 <<
NCT00356096	Restless Legs Syndrome ... 展开 >> Depression 收起 <<	Phase 4	Completed	-	-
NCT01320982	Schizophrenia ... 展开 >> Schizoaffective Disorder 收起 <<	Phase 3	Unknown	July 2012	Israel ... 展开 >> Sheba Medical Center Not yet recruiting Ramat-Gan, Israel, 52621 Contact: Mark Weiser, MD +972-52-6666575 mweiser@netvision.net.il Contact: Katya Rubinstein, MA +972-3-5303454 rubins.katya@gmail.com Principal Investigator: Mark Weiser, MD Romania Clinica de Psihiatrie Not yet recruiting Arad, Romania Contact: Delia Podea, MD 0722 583 757 deliapodea@gmail.com Principal Investigator: Delia Podea, MD Spitalul de Psihiatrie Botosani, Sectia Psihiatrie Not yet recruiting Botosani, Romania Contact: Nicolae Vlad, MD 0741 335 034 v_nicolae@yahoo.com Principal Investigator: Nicolae Vlad, MD Spitalul Clinic de Psihiatrie "Prof. Dr. Alex. Obregia" Not yet recruiting Bucuresti, Romania Contact: Dan Prelipceanu, MD 0722 300 227 prelipceanudan@yahoo.com Principal Investigator: Dan Prelipceanu, MD Spitalul Clinic de Psihiatrie "Prof. Dr. Alex. Obregia" Not yet recruiting Bucuresti, Romania Contact: Gabriela Marian, MD 0723 569 620 gabi.marian@yahoo.com Principal Investigator: Marian Gabriela, MD Spitalul Clinic de Psihiatrie "Prof. Dr. Alex. Obregia" Not yet recruiting Bucuresti, Romania Contact: Maria Ladea, MD 0724 371 042 marialadea@gmail.com Principal Investigator: Maria Ladea, MD Spitalul Clinic de Psihiatrie "Prof. Dr. Alex. Obregia" Not yet recruiting Bucuresti, Romania Contact: Dorina-Valerica Sima, MD 0723 859 570 dorinasima@yahoo.com Principal Investigator: Dorina-Valerica Sima, MD Spitalul Clinic de Psihiatrie "Prof. Dr. Alex. Obregia" Not yet recruiting Bucuresti, Romania Contact: Maria-Silvia Trandafir, MD 0724 275 572 silviatrandafir2004@yahoo.com Principal Investigator: Maria-Silvia Trandafir, MD Spitalul Clinic de Psihiatrie "Prof. Dr. Alex. Obregia" Not yet recruiting Bucuresti, Romania Contact: Ana-Liana Giurgiuca, MD 0722 378 967 giurgiuca_liana@yahoo.com Principal Investigator: Ana-Liana Giurgiuca, Md Spitalul Clinic de Psihiatrie "Prof. Dr. Alex. Obregia" Not yet recruiting Bucuresti, Romania Contact: Valentin Matei, MD 0723 640 918 petcu_camelia@yahoo.com Principal Investigator: Valentin Matei, MD Sp. Jud. "Prof. Dr.O. Fodor" Not yet recruiting Cluj-Napoca, Romania Contact: Mircea-Alexandru Birt, MD 0721 012 220 mirceabirt@yahoo.com Principal Investigator: Mircea-Alexandru Birt, MD Spitalul Clinic Judetean de Urgenta Cluj Not yet recruiting Cluj-Napoca, Romania Contact: Ioana-Valentina Miclutia, MD 0722 796 067 ioanamiclu@yahoo.com Principal Investigator: Ioana-Valentina Miclutia, MD Spitalul Clinic de Psihiatrie Socola, Iasi Not yet recruiting Iasi, Romania Contact: Serban Turliuc, MD 0745 203 002 serban_turliuc@yahoo.com Principal Investigator: Serban Turliuc, MD Spitalul Clinic de Psihiatrie Socola, Iasi Not yet recruiting Iasi, Romania Contact: Nicoleta Cartas, MD 0724 576 261 nicoletacartas_socola@yahoo.com Principal Investigator: Nicoleta Cartas, MD 收起 <<
NCT00239486	Restless Legs Syndrome	Phase 2	Completed	-	Finland ... 展开 >> NEURO Helsinki, Finland, FIN-00250 收起 <<
NCT00651183	-		Completed	-	-
NCT00086307	-		Completed	-	-
NCT00086307	Major Depression	Phase 2	Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT00721279	-		Completed	-	-
NCT00721279	-		Completed	-	-
NCT01097421	-		Completed	-	-
NCT00375284	Restless Legs Syndrome	Phase 4	Completed	-	-
NCT01170091	-		Completed	-	Korea, Republic of ... 展开 >> Boehringer Ingelheim Investigational Site 1 Busan, Korea, Republic of Boehringer Ingelheim Investigational Site 2 Busan, Korea, Republic of Boehringer Ingelheim Investigational Site 3 Busan, Korea, Republic of Boehringer Ingelheim Investigational Site 32 Daegu, Korea, Republic of Boehringer Ingelheim Investigational Site 33 Daegu, Korea, Republic of Boehringer Ingelheim Investigational Site 34 Daejeon, Korea, Republic of Boehringer Ingelheim Investigational Site 35 Daejeon, Korea, Republic of Boehringer Ingelheim Investigational Site 36 Deajeon, Korea, Republic of Boehringer Ingelheim Investigational Site 25 Gwangju, Korea, Republic of Boehringer Ingelheim Investigational Site 26 Gwangju, Korea, Republic of Boehringer Ingelheim Investigational Site 27 Gwangju, Korea, Republic of Boehringer Ingelheim Investigational Site 28 Gwangju, Korea, Republic of Boehringer Ingelheim Investigational Site 29 Gwangju, Korea, Republic of Boehringer Ingelheim Investigational Site 30 Gwangju, Korea, Republic of Boehringer Ingelheim Investigational Site 31 Gwangju, Korea, Republic of Boehringer Ingelheim Investigational Site 10 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 11 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 12 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 13 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 14 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 15 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 16 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 17 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 18 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 19 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 20 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 21 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 22 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 23 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 24 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 4 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 5 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 6 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 7 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 8 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 9 Seoul, Korea, Republic of 收起 <<
NCT00140218	Amyotrophic Lateral Sclerosis	Phase 1 Phase 2	Completed	-	United States, Pennsylvania ... 展开 >> David Lacomis MD Pittsburgh, Pennsylvania, United States United States, Virginia University of Virginia Charlottesville, Virginia, United States, 22908 收起 <<
NCT00651183	-		Completed	-	-
NCT02236741	-		Completed	-	-
NCT00479401	Early Parkinson Disease (Early... 展开 >> PD) 收起 <<	Phase 3	Completed	-	-
NCT00558467	Tourette Syndrome	Phase 2	Completed	-	United States, Florida ... 展开 >> 248.644.0026 Boehringer Ingelheim Investigational Site Bradenton, Florida, United States 248.644.0025 Boehringer Ingelheim Investigational Site Tampa, Florida, United States United States, Georgia 248.644.0006 Boehringer Ingelheim Investigational Site Columbus, Georgia, United States United States, Illinois 248.644.0012 Boehringer Ingelheim Investigational Site Chicago, Illinois, United States United States, Massachusetts 248.644.0005 Boehringer Ingelheim Investigational Site Cambridge, Massachusetts, United States United States, New York 248.644.0003 Boehringer Ingelheim Investigational Site Manhasset, New York, United States 248.644.0009 Boehringer Ingelheim Investigational Site New York, New York, United States 248.644.0018 Boehringer Ingelheim Investigational Site New York, New York, United States 248.644.0013 Boehringer Ingelheim Investigational Site Orangeburg, New York, United States United States, Oklahoma 248.644.0029 Boehringer Ingelheim Investigational Site Oklahoma City, Oklahoma, United States United States, Rhode Island 248.644.0010 Boehringer Ingelheim Investigational Site Providence, Rhode Island, United States United States, Tennessee 248.644.0030 Boehringer Ingelheim Investigational Site Memphis, Tennessee, United States United States, Texas 248.644.0008 Boehringer Ingelheim Investigational Site Houston, Texas, United States United States, Virginia 248.644.0023 Boehringer Ingelheim Investigational Site Norfolk, Virginia, United States Germany 248.644.49001 Boehringer Ingelheim Investigational Site Hannover, Germany 248.644.49004 Boehringer Ingelheim Investigational Site Ulm, Germany 收起 <<
NCT02172573	Parkinson Disease	Phase 3	Completed	-	-
NCT00558467	-		Completed	-	-
NCT01170091	-		Completed	-	-
NCT00479401	-		Completed	-	-
NCT00472199	-		Completed	-	-
NCT00472199	Restless Legs Syndrome	Phase 4	Completed	-	-
NCT00344994	Restless Legs Syndrome	Phase 4	Completed	-	United States, Georgia ... 展开 >> Medical College of Georgia Augusta, Georgia, United States, 30912 收起 <<
NCT00597896	Bipolar Disorder	Phase 4	Completed	-	United States, New York ... 展开 >> North Shore - Long Island Jewish Health System Glen Oaks, New York, United States, 11004 收起 <<
NCT02231294	-		Completed	-	-
NCT00893841	Bipolar Depression	Phase 2	Completed	-	United States, California ... 展开 >> Affiliated Research Institute San Diego, California, United States, 92108 United States, Washington Eastside Therapeutic Resource Kirkland, Washington, United States, 98033 Canada, Alberta Dr. P. Chokka Edmonton, Alberta, Canada, T6L 6W6 Canada, British Columbia Penticton Regional Penticton, British Columbia, Canada, V2A 4M4 Copeman Neuroscience Centre Vancouver, British Columbia, Canada, V6Z 2L4 Canada, Nova Scotia AK Munshi Medical Inc. Sydney, Nova Scotia, Canada, B1S 2E8 Canada, Ontario Regional Mental Health Care - London London, Ontario, Canada, N6A 4H1 Canada, Quebec Hôpital Louis-H.Lafontaine Montreal, Quebec, Canada, H1N 3M5 Canada Clinique Marie Fitzbach Quebec, Canada, G1R 2W8 收起 <<
NCT02260024	Healthy	Phase 1	Completed	-	-
NCT00597896	-		Completed	-	-
NCT02248207	-		Completed	-	-
NCT00297778	Parkinson Disease ... 展开 >> Depression 收起 <<	Phase 4	Completed	-	-
NCT02033369	Major Depressive Disorder	Phase 4	Active, not recruiting	July 2018	United States, New York ... 展开 >> New York State Psychiatric Institute New York, New York, United States, 10032 收起 <<
NCT03329508	Parkinson Disease	Phase 3	Recruiting	December 30, 2019	-
NCT00144300	Parkinson Disease	Phase 4	Completed	-	-
NCT00402233	Parkinson Disease	Phase 4	Completed	-	-
NCT00297778	-		Completed	-	-
NCT02177357	Parkinson Disease	Phase 3	Completed	-	-
NCT02033369	-		Active, not recruiting	-	-
NCT02231918	Restless Legs Syndrome	Phase 2	Completed	-	-
NCT02231918	-		Completed	-	-
NCT00231959	Depression	Phase 4	Completed	-	United States, Massachusetts ... 展开 >> Depression Clinical and Research Program, Massachusetts General Hospital Boston, Massachusetts, United States, 02114 收起 <<
NCT00144300	-		Completed	-	-
NCT01214109	-		Completed	-	-
NCT00402233	-		Completed	-	-
NCT00991276	Restless Legs Syndrome	Phase 3	Completed	-	-
NCT01191944	-		Completed	-	-
NCT01191944	Parkinson Disease	Phase 3	Completed	-	China ... 展开 >> 248.671.86004 Boehringer Ingelheim Investigational Site Beijing, China 248.671.86006 Boehringer Ingelheim Investigational Site Beijing, China 248.671.86007 Boehringer Ingelheim Investigational Site Beijing, China 248.671.86020 Boehringer Ingelheim Investigational Site Beijing, China 248.671.86012 Boehringer Ingelheim Investigational Site Chengdu, China 248.671.86013 Boehringer Ingelheim Investigational Site Chongqing, China 248.671.86014 Boehringer Ingelheim Investigational Site Chongqing, China 248.671.86008 Boehringer Ingelheim Investigational Site Guangzhou, China 248.671.86009 Boehringer Ingelheim Investigational Site Guangzhou, China 248.671.86017 Boehringer Ingelheim Investigational Site Hangzhou, China 248.671.86018 Boehringer Ingelheim Investigational Site Hangzhou, China 248.671.86005 Boehringer Ingelheim Investigational Site Jinan, China 248.671.86002 Boehringer Ingelheim Investigational Site Nanjing, China 248.671.86001 Boehringer Ingelheim Investigational Site Shanghai, China 248.671.86003 Boehringer Ingelheim Investigational Site Shanghai, China 248.671.86010 Boehringer Ingelheim Investigational Site Shanghai, China 248.671.86011 Boehringer Ingelheim Investigational Site Shenyang, China 248.671.86019 Boehringer Ingelheim Investigational Site Suzhou, China 248.671.86015 Boehringer Ingelheim Investigational Site Wuhan, China 248.671.86016 Boehringer Ingelheim Investigational Site Wuhan, China 收起 <<
NCT00654498	Restless Legs Syndrome	Phase 3	Completed	-	China ... 展开 >> 248.630.04 Boehringer Ingelheim Investigational Site Beijing, China 248.630.05 Boehringer Ingelheim Investigational Site Beijing, China 248.630.06 Boehringer Ingelheim Investigational Site Beijing, China 248.630.07 Boehringer Ingelheim Investigational Site Beijing, China 248.630.08 Boehringer Ingelheim Investigational Site Beijing, China 248.630.15 Boehringer Ingelheim Investigational Site Guangzhou, China 248.630.14 Boehringer Ingelheim Investigational Site Haerbin, China 248.630.10 Boehringer Ingelheim Investigational Site Hangzhou, China 248.630.09 Boehringer Ingelheim Investigational Site Nanjing, China 248.630.12 Boehringer Ingelheim Investigational Site Qingdao, China 248.630.01 Boehringer Ingelheim Investigational Site Shanghai, China 248.630.02 Boehringer Ingelheim Investigational Site Shanghai, China 248.630.03 Boehringer Ingelheim Investigational Site Shanghai, China 248.630.16 Boehringer Ingelheim Investigational Site Suzhou, China 248.630.13 Boehringer Ingelheim Investigational Site Wuhan, China 248.630.11 Boehringer Ingelheim Investigational Site Xian, Shanxi Province, China 收起 <<
NCT00654498	-		Completed	-	-
NCT01214109	Healthy	Phase 1	Completed	-	China ... 展开 >> 248.665.86002 Boehringer Ingelheim Investigational Site Beijing, China 收起 <<
NCT00689052	Fibromyalgia	Phase 2	Terminated	-	-
NCT01525641	-		Completed	-	-
NCT01525641	-		Completed	-	-
NCT02264132	Healthy	Phase 1	Completed	-	-
NCT02231905	Parkinson Disease	Phase 4	Completed	-	-
NCT00390689	-		Completed	-	-
NCT00321854	-		Completed	-	-
NCT00689052	-		Terminated	-	-
NCT00560508	Parkinson Disease	Phase 2 Phase 3	Completed	-	Japan ... 展开 >> 248.610.019 Boehringer Ingelheim Investigational Site Akashi, Hyogo, Japan 248.610.020 Boehringer Ingelheim Investigational Site Akita, Akita, Japan 248.610.006 Boehringer Ingelheim Investigational Site Aomori, Aomori, Japan 248.610.017 Boehringer Ingelheim Investigational Site Asahikawa, Hokkaido, Japan 248.610.018 Boehringer Ingelheim Investigational Site Asahikawa, Hokkaido, Japan 248.610.001 Boehringer Ingelheim Investigational Site Bunkyo-ku, Tokyo, Japan 248.610.014 Boehringer Ingelheim Investigational Site Fuchu, Tokyo, Japan 248.610.011 Boehringer Ingelheim Investigational Site Fukuoka, Fukuoka, Japan 248.610.015 Boehringer Ingelheim Investigational Site Iwamizawa,Hokkaido, Japan 248.610.003 Boehringer Ingelheim Investigational Site Kodaira, Tokyo, Japan 248.610.008 Boehringer Ingelheim Investigational Site Kyoto, Kyoto, Japan 248.610.021 Boehringer Ingelheim Investigational Site Kyoto, Kyoto, Japan 248.610.010 Boehringer Ingelheim Investigational Site Morioka, Iwate, Japan 248.610.005 Boehringer Ingelheim Investigational Site Okayama, Okayama, Japan 248.610.012 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan 248.610.004 Boehringer Ingelheim Investigational Site Sagamihara, Kanagawa, Japan 248.610.009 Boehringer Ingelheim Investigational Site Shimogyo-ku, Kyoto, Kyoto, Japan 248.610.007 Boehringer Ingelheim Investigational Site Shiroishi, Miyagi, Japan 248.610.002 Boehringer Ingelheim Investigational Site Takamatsu, Kagawa, Japan 收起 <<
NCT00991276	-		Completed	-	-
NCT00390689	Idiopathic Restless Legs Syndr... 展开 >>ome 收起 <<	Phase 3	Completed	-	Japan ... 展开 >> 248.627.037 Boehringer Ingelheim Investigational Site Aichi-gun, Aichi, Japan 248.627.014 Boehringer Ingelheim Investigational Site Fujisawa, Kanagawa, Japan 248.627.029 Boehringer Ingelheim Investigational Site Fukuoka, Fukuoka, Japan 248.627.032 Boehringer Ingelheim Investigational Site Hiroshima, Hiroshima, Japan 248.627.030 Boehringer Ingelheim Investigational Site Kagoshima, Kagoshima, Japan 248.627.013 Boehringer Ingelheim Investigational Site Kanagawa, Yokohama, Japan 248.627.033 Boehringer Ingelheim Investigational Site Kanazawa, Ishikawa, Japan 248.627.027 Boehringer Ingelheim Investigational Site Kawasaki, Kanagawa, Japan 248.627.023 Boehringer Ingelheim Investigational Site Kitakyusyu, Fukuoka, Japan 248.627.024 Boehringer Ingelheim Investigational Site Kitakyusyu, Fukuoka, Japan 248.627.022 Boehringer Ingelheim Investigational Site Kochi, Kochi, Japan 248.627.034 Boehringer Ingelheim Investigational Site Kodaira, Tokyo, Japan 248.627.038 Boehringer Ingelheim Investigational Site Koriyama, Fukushima, Japan 248.627.041 Boehringer Ingelheim Investigational Site Koriyama, Fukushima, Japan 248.627.039 Boehringer Ingelheim Investigational Site Kumamoto, Kumamoto, Japan 248.627.003 Boehringer Ingelheim Investigational Site Kurume, Fukuoka, Japan 248.627.036 Boehringer Ingelheim Investigational Site Minato-ku, Tokyo, Japan 248.627.025 Boehringer Ingelheim Investigational Site Mitaka-shi, Tokyo, Japan 248.627.015 Boehringer Ingelheim Investigational Site Nagoya, Aichi, Japan 248.627.017 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan 248.627.011 Boehringer Ingelheim Investigational Site Otaru, Hokkaido, Japan 248.627.026 Boehringer Ingelheim Investigational Site Otsu, Shiga, Japan 248.627.002 Boehringer Ingelheim Investigational Site Sakai,Osaka, Japan 248.627.010 Boehringer Ingelheim Investigational Site Sapporo, Hokkaido, Japan 248.627.035 Boehringer Ingelheim Investigational Site Sapporo, Hokkaido, Japan 248.627.012 Boehringer Ingelheim Investigational Site Sendai, Miyagi, Japan 248.627.001 Boehringer Ingelheim Investigational Site Shibuya-ku, Tokyo, Japan 248.627.004 Boehringer Ingelheim Investigational Site Shimotsuga-gun,Tochigi, Japan 248.627.040 Boehringer Ingelheim Investigational Site Shinjuku-ku, Tokyo, Japan 248.627.018 Boehringer Ingelheim Investigational Site Takatsuki,Osaka, Japan 248.627.028 Boehringer Ingelheim Investigational Site Tokorozawa, Saitama, Japan 248.627.019 Boehringer Ingelheim Investigational Site Tokushima, Tokushima, Japan 248.627.016 Boehringer Ingelheim Investigational Site Toyohashi, Aichi, Japan 248.627.031 Boehringer Ingelheim Investigational Site Urasoe, Okinawa, Japan 收起 <<
NCT02261103	Healthy	Phase 1	Completed	-	-
NCT00275275	Parkinson Disease	Phase 3	Completed	-	United States, Kansas ... 展开 >> University of Kansas Medical Center Kansas City, Kansas, United States, 66160 收起 <<
NCT00560508	-		Completed	-	-
NCT00321854	Parkinson Disease	Phase 4	Completed	-	-
NCT01470859	Idiopathic Parkinson's Disease	Not Applicable	Completed	-	China, Shanghai ... 展开 >> Huashan Hospital Affiliated to Fudan University Shanghai, Shanghai, China, 200040 收起 <<
NCT01470859	-		Completed	-	-
NCT00275275	-		Completed	-	-
NCT00647296	Amyotrophic Lateral Sclerosis	Phase 2	Completed	-	-
NCT01066897	-		Terminated(Lack of funding pre... 展开 >>vented further recruitment) 收起 <<	-	-
NCT01066897	Depression	Phase 4	Terminated(Lack of funding pre... 展开 >>vented further recruitment) 收起 <<	-	United States, California ... 展开 >> Stanford University School of Medicine Stanford, California, United States, 94305 收起 <<
NCT00601523	Parkinson Disease	Phase 3	Completed	-	-
NCT00601523	-		Completed	-	-
NCT02248168	-		Completed	-	-
NCT01074463	Healthy	Phase 1	Completed	-	United States, North Dakota ... 展开 >> PRACS Institute, Ltd. Fargo, North Dakota, United States, 58104 收起 <<
NCT01074463	-		Completed	-	-
NCT01074450	Healthy	Phase 1	Completed	-	United States, North Dakota ... 展开 >> PRACS Institute, Ltd. Fargo, North Dakota, United States, 58104 收起 <<
NCT01074450	-		Completed	-	-
NCT00577460	Parkinson Disease	Phase 3	Completed	-	-
NCT02248142	-		Completed	-	-
NCT02248155	-		Completed	-	-
NCT01515774	Parkinson's Disease	Phase 4	Unknown	October 2012	Korea, Republic of ... 展开 >> Seoul National University Hospital Recruiting Seoul, Korea, Republic of, 110-744 Contact: Beom S. Jeon, MD, PhD 82-2-2072-2876 brain@snu.ac.kr Contact: Ji Y Yun, MD 82-2-2072-0359 dream-yoon@hanmail.net Principal Investigator: Beom S. Jeon, MD, PhD Sub-Investigator: Han-Joon Kim, MD Sub-Investigator: Ji Y Yun, MD Sub-Investigator: Young Eun Kim, MD 收起 <<
NCT00558025	-		Completed	-	-
NCT01424163	Amyotrophic Lateral Sclerosis	Phase 1	Completed	-	United Kingdom ... 展开 >> Research Site London, United Kingdom 收起 <<
NCT02236728	-		Completed	-	-
NCT02248220	-		Completed	-	-
NCT00577460	-		Completed	-	-
NCT02248181	-		Completed	-	-
NCT01673724	Parkinson's Disease	Phase 4	Completed	-	Korea, Republic of ... 展开 >> Korea University Ansan Hospital Ansan, Korea, Republic of Inje University Busan Paik Hospital Busan, Korea, Republic of Youngnam University Hospital Daegu, Korea, Republic of Kangwon Nat'l University Hospital Kangwon, Korea, Republic of Inje university Sanggye Paik Hospital Seoul, Korea, Republic of Korea University Anam Hospital Seoul, Korea, Republic of Korea University Guro Hospital Seoul, Korea, Republic of 收起 <<
NCT01281189	Amyotrophic Lateral Sclerosis	Phase 3	Completed	-	-
NCT02397837	Bipolar Disorder	Phase 4	Recruiting	October 31, 2018	United States, Massachusetts ... 展开 >> Brigham and Women's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Megan Shanahan mshanahan2@partners.org United States, New York The Zucker Hillside Hospital Completed Glen Oaks, New York, United States, 11004 Icahn School of Medicine at Mount Sinai Completed New York, New York, United States, 10029 收起 <<
NCT03521635	Parkinson Disease	Phase 4	Recruiting	August 14, 2019	China ... 展开 >> Beijing Hospital Recruiting Beijing, China Contact: Haibo Chen 0086 (010) 85136182 chenhbneuro@263.net The First Afiliated Hospital, Sun Yet-sen University Recruiting Guangzhou, China, 510080 Contact: Ling Chen +86 13543433955 1678270523@qq.com Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Recruiting Shanghai, China, 200025 Contact: Shengdi Chen 86-21-64370045/64315052 ruijincsd@126.com Tianjin Medical University General Hospital Recruiting Tianjin, China, 30052 Contact: Fudong Shi 0086（022）60362255 sfdclinicalstudy@sina.com 收起 <<
NCT01361009	-		Completed	-	-
NCT03681509	Pramipexole E... 展开 >>motions Motivation Reward Dopamine 收起 <<	Not Applicable	Recruiting	September 2019	United Kingdom ... 展开 >> Dept of Psychiatry, University of Oxford Recruiting Oxford, Oxfordshire, United Kingdom, OX3 7JX Contact: Michael Browning, MB.BS +44 (0)1865 6183161 michael.browning@psych.ox.ac.uk Principal Investigator: Michael Browning, MB.BS 收起 <<
NCT01361009	-		Completed	-	-
NCT01424176	Amyotrophic Lateral Sclerosis ... 展开 >> Renal Insufficiency 收起 <<	Phase 1	Completed	-	United States, Florida ... 展开 >> Research Site Orlando, Florida, United States, 32809 United States, Minnesota Research Site Brooklyn Center, Minnesota, United States, 55430 收起 <<
NCT01441284	Essential Tremor	Phase 3	Withdrawn(Lack of financial su... 展开 >>pport) 收起 <<	December 2018	Hungary ... 展开 >> Department of Neurology, University of Pécs Pécs, Baranya Megye, Hungary, H-7623 Kaposi Mór County Hospital Kaposvár, Somogy Megye, Hungary, H-7400 收起 <<
NCT01511029	Amyotrophic Lateral Sclerosis	Phase 1	Completed	-	United States, Kansas ... 展开 >> Research Site Overland Park, Kansas, United States 收起 <<
NCT01449578	Amyotrophic Lateral Sclerosis	Phase 1	Completed	-	United States, Kansas ... 展开 >> Research Site Overland Park, Kansas, United States 收起 <<
NCT01597310	Healthy Volunteers	Phase 1	Completed	-	United States, Kansas ... 展开 >> Research Site Overland Park, Kansas, United States 收起 <<
NCT00558025	Parkinson Disease	Phase 3	Completed	-	France ... 展开 >> 248.636.3303A Boehringer Ingelheim Investigational Site Aix en Provence, France 248.636.3303B Boehringer Ingelheim Investigational Site Aix en Provence, France 248.636.3303C Boehringer Ingelheim Investigational Site Aix en Provence, France 248.636.3307C Boehringer Ingelheim Investigational Site Bron cedex, France 248.636.3309B Boehringer Ingelheim Investigational Site Clermont Ferrand, France 248.636.3305A Boehringer Ingelheim Investigational Site Créteil, France 248.636.3305B Boehringer Ingelheim Investigational Site Créteil, France 248.636.3313A Boehringer Ingelheim Investigational Site Dijon cedex, France 248.636.3304A Boehringer Ingelheim Investigational Site Evreux, France 248.636.3308B Boehringer Ingelheim Investigational Site Lille cedex, France 248.636.3308C Boehringer Ingelheim Investigational Site Lille cedex, France 248.636.3308D Boehringer Ingelheim Investigational Site Lille cedex, France 248.636.3308E Boehringer Ingelheim Investigational Site Lille cedex, France 248.636.3302A Boehringer Ingelheim Investigational Site Marseille cedex 5, France 248.636.3302B Boehringer Ingelheim Investigational Site Marseille cedex 5, France 248.636.3306B Boehringer Ingelheim Investigational Site Montpellier, France 248.636.3312A Boehringer Ingelheim Investigational Site Rouen, France 248.636.3312B Boehringer Ingelheim Investigational Site Rouen, France 248.636.3311A Boehringer Ingelheim Investigational Site Strasbourg, France 248.636.3301A Boehringer Ingelheim Investigational Site Toulouse cedex, France 248.636.3301B Boehringer Ingelheim Investigational Site Toulouse cedex, France 248.636.3301D Boehringer Ingelheim Investigational Site Toulouse cedex, France Germany 248.636.49006 Boehringer Ingelheim Investigational Site Achim bei Bremen, Germany 248.636.49003 Boehringer Ingelheim Investigational Site Berlin-Steglitz, Germany 248.636.49004 Boehringer Ingelheim Investigational Site Berlin, Germany 248.636.49007 Boehringer Ingelheim Investigational Site Berlin, Germany 248.636.49008 Boehringer Ingelheim Investigational Site Berlin, Germany 248.636.49002 Boehringer Ingelheim Investigational Site Gera, Germany 248.636.49001 Boehringer Ingelheim Investigational Site Karlsruhe, Germany 248.636.49005 Boehringer Ingelheim Investigational Site Unterhaching, Germany Netherlands 248.636.31005 Boehringer Ingelheim Investigational Site `s-hertogenbosch, Netherlands 248.636.31002 Boehringer Ingelheim Investigational Site Geldrop, Netherlands 248.636.31003 Boehringer Ingelheim Investigational Site Helmond, Netherlands 248.636.31006 Boehringer Ingelheim Investigational Site Maastricht, Netherlands 248.636.31004 Boehringer Ingelheim Investigational Site Nijmegen, Netherlands 248.636.31001 Boehringer Ingelheim Investigational Site Sittard, Netherlands 收起 <<
NCT00931944	Amyotrophic Lateral Sclerosis	Phase 2	Completed	-	United States, Arkansas ... 展开 >> University of Arkansas for Medical Sciences Little Rock, Arkansas, United States, 72205 United States, California UCLA, Dept. of Neurology - Neuromuscular/ALS Research Center Los Angeles, California, United States, 90095 The Forbes Norris MDA/ALS Research Center San Francisco, California, United States, 94115 United States, Florida University of Miami Miller School of Medicine Miami, Florida, United States, 33136 United States, Kansas University of Kansas Medical Center Kansas City, Kansas, United States, 66160 United States, Maryland Johns Hopkins University School of Medicine Baltimore, Maryland, United States, 21228 United States, Massachusetts Massachusettes General Hospital Boston, Massachusetts, United States, 02129 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Nebraska Bryan LGH Medical Center East Lincoln, Nebraska, United States, 68506 United States, New York Columbia University, Lou Gehrig MDA/ALS Research Center New York, New York, United States, 10032 SUNY Upstate Medical University Syracuse, New York, United States, 13210 United States, Pennsylvania Penn State Hershey Medical Center Hershey, Pennsylvania, United States, 17033 Drexel University College Of Medicine Philadelphia, Pennsylvania, United States, 19102 University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania, United States, 15213 United States, Tennessee Vanderbilt University Medical Center Nashville, Tennessee, United States, 37232 United States, Texas University of Texas Health Sciences Center of San Antonio San Antonio, Texas, United States, 78229 United States, Utah University of Utah Salt Lake City, Utah, United States, 84132 United States, Virginia University of Virginia Health System Charlottesville, Virginia, United States, 22908 United States, Washington University of Washington Seattle, Washington, United States, 98195 收起 <<
NCT01388478	Alzheimer's Disease	Phase 2	Completed	-	United States, Kansas ... 展开 >> University of Kansas Medical Center Kansas City, Kansas, United States, 66160 收起 <<
NCT01106053	Binge Eating Disorder	Phase 3	Withdrawn(No participants were... 展开 >> recruited and study has been closed.) 收起 <<	-	-
NCT01607034	Healthy Volunteers	Phase 1	Completed	-	United States, Minnesota ... 展开 >> Research Site St. Paul, Minnesota, United States 收起 <<
NCT03765138	PTSD MDD	Phase 3	Recruiting	March 1, 2020	United States, New York ... 展开 >> New York State Psychiatric Institute Recruiting New York, New York, United States, 10032 Contact: Yuval Neria, PhD 646-774-8092 Yuval.neria@nyspi.columbia.edu Contact: Franklin Schneier, MD 646 823 3863 Franklin.schneier@nyspi.columbia.edu 收起 <<
NCT02660060	Healthy	Not Applicable	Completed	-	Indonesia ... 展开 >> PT Equilab International Jakarta, Indonesia, 12430 收起 <<
NCT01651377	Cocaine Addiction ... 展开 >> Cocaine Abuse Cocaine Dependence Substance Abuse 收起 <<	Phase 1	Completed	-	United States, Texas ... 展开 >> Michael E. DeBakey VA Medical Center Houston, Texas, United States, 77030 收起 <<
NCT01536249	Amyotrophic Lateral Sclerosis	Phase 1	Completed	-	United States, Kansas ... 展开 >> Research Site Overland Park, Kansas, United States 收起 <<
NCT02101138	Hypereosinophilic Syndrome	Phase 2	Active, not recruiting	October 23, 2019	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT02217332	Chronic Sinusitis With Nasal P... 展开 >>olyps and Eosinophilia 收起 <<	Phase 2	Completed	-	United States, Florida ... 展开 >> ENT Associates of South Florida Boca Raton, Florida, United States, 33487 United States, Maryland Johns Hopkins University Baltimore, Maryland, United States, 21205 United States, Massachusetts Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 United States, North Carolina Wake Research Associates Raleigh, North Carolina, United States, 27612 United States, Pennsylvania University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania, United States, 15213 United States, Virginia University of Virginia Charlottesville, Virginia, United States, 22903 收起 <<
NCT01622088	Amyotrophic Lateral Sclerosis	Phase 3	Terminated(The Initial Phase 3... 展开 >> Study (NCTO1281189) did not meet its primary efficacy endpoint.) 收起 <<	-	-
NCT03430596	Extrapyramidal Syndrome	Early Phase 1	Not yet recruiting	June 2019	China, Shanghai ... 展开 >> Shanghai Mental Health Center Shanghai, Shanghai, China, 200030 收起 <<

产品名称	D1 receptor ↓ ↑	D2 receptor ↓ ↑	D3 receptor ↓ ↑	D4 receptor ↓ ↑	D5 receptor ↓ ↑	DAT ↓ ↑	Dopamine receptor ↓ ↑	其他靶点	纯度
Penfluridol	+ Dopamine receptor, Ki: 1.6 μM								98%
Ansofaxine HCl	++ Dopamine receptor, IC50: 491 nM								99%
Tetrahydroberberine		+ D2 receptor, pKi: 6.08							98+%
Prochlorperazine Maleate		✔							98% (HPLC)
Olanzapine		✔							99+%
Trifluoperazine		++++ Dopamine D2 receptor, IC50: 1.1 nM							98%
Ropinirole HCl		++ D2 receptor, Ki: 29 nM							99%
Lurasidone		++++ D2 receptor, Ki: 1 nM							98%
Levosulpiride		✔							99+%
Pridopidine		✔							95%
Metoclopramide		✔					✔		99+%
Molindone HCl		✔							99%
Sulpiride		✔							99+%
Perospirone		++++ D2 receptor, Ki: 1.4 nM							99%
Perospirone HCl		++++ D2 receptor, Ki: 1.4 nM							99%
Phenothiazine		✔							98%
Pimozide	+ Dopamine D1 receptor, Ki: 6600 nM	+++ Dopamine D2 receptor, Ki: 3.0 nM	++++ Dopamine D3 receptor, Ki: 0.83 nM						98%
Rotundine	++ D1 receptor, IC50: 166 nM	+ D2 receptor, IC50: 1.47 μM	+ D3 receptor, IC50: 3.25 μM						98%
Domperidone		✔							99+%
ONC206		✔							99%
Pimethixene maleate	++ Dopamine D1 Receptor, pKi: 6.37	+++ Dopamine D2 Receptor, pKi: 8.19		++ Dopamine D4.4 Receptor, pKi: 7.54					97%
Loxapine succinate	++ D1 receptor (human), Ki: 26 nM D2 receptor (Human), Ki: 62 nM	++ D2 receptor (human), Ki: 24 nM D2 receptor (bovine), Ki: 26 nM		+++ D4 receptor (human), Ki: 7.5 nM					98%
Chlorprothixene	+++ D1 receptor, Ki: 18 nM	+++ D2 receptor, Ki: 2.96 nM	+++ D3 receptor, Ki: 4.56 nM		+++ D5 receptor, Ki: 9 nM				99%
SCH-23390 HCl	++++ D1 dopamine receptor, Ki: 0.2 nM				++++ D5 dopamine receptor, Ki: 0.3 nM				98%
MPP+ iodide						✔			97%
σ1 Receptor antagonist-1						+ DAT, pKi: 5.8			97%
Benztropine mesylate						++ DAT, IC50: 118 nM			98%
Azaperone							✔		98%
Ziprasidone HCl							✔		98+%
Paliperidone							✔		98%
Alizapride HCl							✔		99+%
Amisulpride							✔		98%
Quetiapine hemifumarate							✔	Adrenergic Receptor	98%
Clozapine N-oxide							✔		99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

CAS号	104632-28-2
分子式	C₁₀H₁₇N₃S
分子量	211.33
SMILES Code	NC1=NC2=C(C[C@H](NCCC)CC2)S1
MDL No.	MFCD09033169

别名	(R)-普拉克索 ;(R)-Pramipexole; R-(+)-Pramipexole; KNS-760704
运输	蓝冰
InChI Key	FASDKYOPVNHBLU-SSDOTTSWSA-N
Pubchem ID	59868

Dexpramipexole/右旋普拉克索 {[allProObj[0].p_purity_real_show]}

Dexpramipexole/右旋普拉克索纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Dexpramipexole/右旋普拉克索质控信息

Dexpramipexole/右旋普拉克索生物活性

Dexpramipexole/右旋普拉克索临床研究

Dexpramipexole/右旋普拉克索参考文献

Dexpramipexole/右旋普拉克索实验方案

Dexpramipexole/右旋普拉克索技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Dexpramipexole/右旋普拉克索 {[allProObj[0].p_purity_real_show]}

Dexpramipexole/右旋普拉克索 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Dexpramipexole/右旋普拉克索 质控信息

Dexpramipexole/右旋普拉克索 生物活性

Dexpramipexole/右旋普拉克索 临床研究

Dexpramipexole/右旋普拉克索 参考文献

Dexpramipexole/右旋普拉克索 实验方案

Dexpramipexole/右旋普拉克索 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Dexpramipexole/右旋普拉克索纯度/质量文件产品仅供科研

Dexpramipexole/右旋普拉克索质控信息

Dexpramipexole/右旋普拉克索生物活性

Dexpramipexole/右旋普拉克索临床研究

Dexpramipexole/右旋普拉克索参考文献

Dexpramipexole/右旋普拉克索实验方案

Dexpramipexole/右旋普拉克索技术信息